VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer.
Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development.
Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024.
Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology.
How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence.
'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.'
'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.'
About VivoSim Labs
VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
ContactInvestor Relationsinfo@vivosim.aiVivoSim Labs, Inc.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
18 minutes ago
- CNBC
Why Wall Street kept sending the S&P 500, Nasdaq to fresh records this week
The stock market ended the week higher as Wall Street speculated on how a spate of economic releases would impact the Federal Reserve's next interest rate decision. The S & P 500 and Nasdaq both gained nearly 1% over the past five sessions. Both benchmark gauges hit several record closes this week, with the S & P 500 reaching the milestone on Tuesday, Wednesday, and Thursday. The tech-heavy Nasdaq closed at record highs on Tuesday and Wednesday. Both indexes hit all-time intraday highs on Friday but closed the session modestly lower. Inflation data Stocks were pushed much higher on Tuesday, which carried the week, after the July consumer price index showed inflation had cooled more than expected. This caused Fed rate cut expectations for September to rise. The stock market's run continued into Wednesday's session. On Thursday, however, stocks lost some momentum after July's producer price index indicated that wholesale inflation rose more than expected last month. Despite higher inflation figures, though, the market odds of a rate cut at the Fed's meeting next month didn't decrease by much, according to the CME FedWatch tool. A second Fed rate cut by the end of the year is also expected. Cisco's quarter Our focus was also on quarterly earnings Wednesday evening from Cisco Systems , the latest addition to the Club's portfolio. Cisco beat analysts' expectations for the top and bottom lines during its fiscal 2025 fourth quarter. The company experienced strong revenue growth within its networking business thanks to the boom in AI infrastructure spending. Orders within the networking business surpassed $800 million during the fiscal fourth quarter, bringing the total to more than $2 billion for fiscal 2025. That's double management's goal for the year. Still, shares slipped after the release due to the significant revenue miss in Cisco's security division. That didn't shake our conviction in the stock, though. The Club reiterated our buy equivalent 1 rating , and maintained our price target of $78. "In a market that rewards AI-exposed companies with lofty valuations, Cisco trades at a very reasonable high teens price-to-earnings multiple. That valuation is too cheap to us," Jeff Marks, director of portfolio analysis for the Club, wrote in his earnings analysis. Later in the week, commentary from one Wall Street firm sent Cisco stock lower again. Shares fell 5.5% on Friday after HSBC downgraded the stock to a hold rating from a buy, and lowered its price target to $69 from $73. Analysts viewed Cisco's quarterly report as lackluster and said more stock gains would be hard to come by. "Though the company reported more than USD2bn of AI infrastructure orders in FY25, strength seems to be getting offset by weakness elsewhere," HSBC wrote in a Thursday note to clients. Record highs Although Cisco stock had a tough week, many other portfolio names experienced big runs. In fact, five Club holdings reached record highs since Monday. In no particular order, here's a breakdown of each. Goldman Sachs briefly reached an all-time high Friday of $749.05. But shares then tumbled 2.2% into the close. BlackRock hit a record Wednesday of $1,171.89. The stock drifted lower to around $1,135 by Friday's close. Broadcom on Wednesday touched $317.35, its highest stock price ever. Nvidia shares jumped to a record of $184.48 on Tuesday. Meta Platforms stock climbed to an all-time high of $796.25 on Friday. Portfolio moves We executed three trades last week, including exiting one position entirely. First, we bought more shares of Starbucks and Palo Alto Networks on Monday after unreasonable sell-offs. On Thursday, we sold the rest of our small Coterra Energy position. It no longer made sense to invest in Coterra in the current economic environment. Jim Cramer talked about this at length during the Club's August Monthly Meeting. We didn't just buy and sell, though. The Club changed ratings on two portfolio names as well. A new piece of Wall Street research led us to downgrade Salesforce on Monday to a hold-equivalent 2 rating. Analysts at Melius Research came out with a note that outlined the headwinds that generative AI could have on software-as-a-service companies like Salesforce. Shares then popped nearly 4% on Friday after filings revealed that Jeff Smith's Starboard Value increased its stake in Salesforce by 47% during the second quarter. That renewed bets that activists will push for change again, as they did with success a couple of years ago. After two terrible weeks, the stock finished this week up almost 1%. Two sessions later, the Club double upgraded Eli Lilly shares to a buy-equivalent 1 rating after CEO David Ricks and other company insiders bought a significant amount of the slumping stock. Health-care stocks, which had been struggling as a sector, have gotten a boost over the past week or so. Lilly stock was our best performer this week, jumping 12%. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Newsweek
18 minutes ago
- Newsweek
Map Shows Tax Cuts Promised by Trump Administration Across 50 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Tax Foundation, a nonpartisan Washington-based think tank, has produced a map forecasting the effects of President Donald Trump's One Big Beautiful Bill Act on taxes across the United States, broken down to the county level. The White House's website reposted the map, noting that the Tax Foundation said Trump's package would "reduce federal taxes on average for individual taxpayers in every state" and create almost 1 million jobs. Newsweek contacted the Tax Foundation for comment on Saturday outside regular office hours. Why It Matters Trump signed his One Big Beautiful Bill, the centerpiece of his economic agenda, into law on July 4 after it narrowly passed both the House and Senate. The Congressional Budget Office has said the legislation will add $2.4 trillion to the U.S. national debt, a forecast that contributed to a falling out between Trump and his previous close confidant Elon Musk. The One Big Beautiful Bill included sweeping tax cuts, reduced spending on Medicaid, and additional funding for the military and border security. It also raised the U.S. debt ceiling by $5 trillion. What To Know On Wednesday, the Tax Foundation published a study forecasting the effects of the One Big Beautiful Bill on taxes paid by the average American on a county-by-county basis between 2026 and 2035. This was accompanied by a map showing the breakdown by county over this period. Two days later, the White House published a news release welcoming the study, which included a screenshot of the Tax Foundation's map taken for 2026. According to the Tax Foundation, the average tax cut per American for 2026 will be $3,752 because of Trump's spending package. This is forecast to fall to $2,505 in 2030 as some measures expire before increasing again to $3,301 in 2035. A map produced by the Tax Foundation showing the effects of President Donald Trump's One Big Beautiful Bill in 2026 on a county-by-county basis. A map produced by the Tax Foundation showing the effects of President Donald Trump's One Big Beautiful Bill in 2026 on a county-by-county basis. Tax Foundation The states forecast to see the largest tax cuts in 2926 are Wyoming ($5,375), Washington ($5,372) and Massachusetts ($5,139). By contrast, the smallest cuts are expected in West Virginia and Mississippi—at $2,503 and $2,401, respectively. In its report, the Tax Foundation described the One Big Beautiful Bill as "the most significant legislative changes to federal tax policy since the 2017 Tax Cuts and Jobs Act," which was passed in Trump's first term. The president's One Big Beautiful Bill contained a number of tax cuts, including extending corporation and income taxes he imposed in the Tax Cuts and Jobs Act. It also raises the cap on state and local tax deductions over the next five years to $40,000 for those making less than $500,000 per year, reduces tax on tips and overtime pay, and phases out some of former President Joe Biden's energy tax credits. The Tax Foundation also projected that the One Big Beautiful Bill would produce about 938,000 jobs "over the long run," including 132,000 in California and 81,000 in Texas. What People Are Saying White House deputy press secretary Anna Kelly said in the news release: "President Trump's One Big Beautiful Bill is the largest, most consequential tax cut on the middle class ever. Now, the Tax Foundation—the leading nonpartisan tax policy nonprofit—confirms that. Between lower inflation, massive investments, and historic tax cuts, all Americans are reaping the benefits of the Trump Economy—and the Golden Age has just begun." What Happens Next While supporters of Trump's One Big Beautiful Bill may be buoyed by the Tax Foundation's report, which suggests it will result in widespread tax reductions and job creation, critics are likely to continue raising concerns about its effects on the national debt and Medicaid cuts.
Yahoo
an hour ago
- Yahoo
CoreWeave Crashes 46% After Lockup--Is This the AI Bargain of the Year or a Falling Knife?
CoreWeave's (NASDAQ:CRWV) post-IPO honeymoon may be ending. After skyrocketing more than fourfold by mid-June, the stock has come back to earthfalling 46% from its June 20 peak. The trigger? Over 80% of Class A shares just became eligible for sale as the IPO lockup expired. That timing came two days after CoreWeave's second earnings report, which revealed a wider-than-expected loss despite a raised 2025 revenue forecast. The stock has already dropped 33% this week alone, with analysts flagging the potential for more downside as early investors head for the exit. Warning! GuruFocus has detected 5 Warning Signs with CRWV. The selloff could create both risk and opportunity. CoreWeave now trades at a roughly $49 billion market cap, down from a June high of $88 billion. Its free floatpreviously under 15%could expand significantly as insiders begin selling. That's likely what spooked the market, according to Roundhill CEO Dave Mazza, who called it a challenging, even confusing setup. Citi's Tyler Radke echoed that sentiment, warning of short-term pressure but suggesting that a more liquid float might attract new buyers. Meanwhile, Nvidia (NASDAQ:NVDA)CoreWeave's key AI chip supplierisn't going anywhere. It actually increased its stake in Q2 to 6.5%, now worth about $2.4 billion. The long-term bull case hasn't vanished. CoreWeave is still spending aggressivelyup to $23 billion this yearto meet rising AI demand, and counts Microsoft as its largest customer. But execution risk is climbing, especially with its all-stock acquisition of Core Scientific looming. Hedge funds like Magnetar and Coatue may opt to ease out slowly to avoid triggering further panic. D.A. Davidson's Gil Luria has a $36 price target, implying over 60% downside from recent levels. Whether this marks a healthy reset or the beginning of a deeper unwind depends on who shows up to buyif anyone does. This article first appeared on GuruFocus.
